RIPK1 and dilated cardiomyopathy: These findings strongly suggest that targeting RIPK1-dependent apoptosis and necroptosis may represent a promising therapeutic strategy for dilated cardiomyopathy in patients carrying TAB2 gene mutations as well as other disease conditions with abnormal RIPK1 kinase activation.